About Achaogen (NASDAQ:AKAO)
Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636
Debt
Debt-to-Equity Ratio0.08%
Current Ratio4.83%
Quick Ratio4.83%
Price-To-Earnings
Trailing P/E Ratio-4.13
Forward P/E Ratio-3.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.18 million
Price / Sales52.34
Cash FlowN/A
Price / CashN/A
Book Value$2.88 per share
Price / Book4.54
Profitability
EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-1,124.10%
Return on Equity-83.14%
Return on Assets-52.31%
Miscellaneous
Employees230
Outstanding Shares44,720,000
Achaogen (NASDAQ:AKAO) Frequently Asked Questions
What is Achaogen's stock symbol?
Achaogen trades on the NASDAQ under the ticker symbol "AKAO."
How were Achaogen's earnings last quarter?
Achaogen (NASDAQ:AKAO) issued its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.21. The biopharmaceutical company had revenue of $1.87 million for the quarter, compared to analysts' expectations of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. View Achaogen's Earnings History.
What price target have analysts set for AKAO?
10 brokers have issued 12-month price objectives for Achaogen's shares. Their forecasts range from $14.00 to $29.00. On average, they expect Achaogen's stock price to reach $23.1250 in the next year. View Analyst Ratings for Achaogen.
What are Wall Street analysts saying about Achaogen stock?
Here are some recent quotes from research analysts about Achaogen stock:
- 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (2/14/2018)
- 2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)
Who are some of Achaogen's key competitors?
Some companies that are related to Achaogen include Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN) and Assembly Biosciences (ASMB).
Who are Achaogen's key executives?
Achaogen's management team includes the folowing people:
- Mr. Blake Wise, CEO & Director (Age 47)
- Dr. Kenneth J. Hillan, Pres of R&D, Pres of Achaogen and Director (Age 57)
- Dr. Floyd E. Romesberg Ph.D., Principal Scientific Founder and Advisor
- Dr. Nathaniel E. David A.B., Ph.D., Principal Entrepreneurial Founder (Age 50)
- Mr. Tobin C. Schilke, Chief Financial Officer & Principal Accounting Officer (Age 43)
Has Achaogen been receiving favorable news coverage?
News headlines about AKAO stock have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achaogen earned a news impact score of -0.06 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Achaogen?
Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achaogen's stock price today?
One share of AKAO stock can currently be purchased for approximately $13.0850.
How big of a company is Achaogen?
Achaogen has a market capitalization of $598.65 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.
How can I contact Achaogen?
Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]
MarketBeat Community Rating for Achaogen (AKAO)
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Achaogen (NASDAQ:AKAO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Achaogen in the last 12 months. Their average twelve-month price target is $23.1250, suggesting that the stock has a possible upside of 76.73%. The high price target for AKAO is $29.00 and the low price target for AKAO is $14.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.91 | 2.90 | 2.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.1250 | $23.7778 | $25.4444 | $26.50 |
| Price Target Upside: | 76.73% upside | 116.16% upside | 128.20% upside | 98.50% upside |
Achaogen (NASDAQ:AKAO) Consensus Price Target History
Achaogen (NASDAQ:AKAO) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Achaogen (NASDAQ:AKAO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 77.41%
Achaogen (NASDAQ AKAO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/4/2018 | Robert W Duggan | Major Shareholder | Buy | 47,361 | $12.44 | $589,170.84 | 6,411,108 |  |
| 4/2/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $12.51 | $250,200.00 | 6,411,108 | |
| 3/28/2018 | Robert W Duggan | Major Shareholder | Buy | 30,000 | $12.44 | $373,200.00 | 6,391,108 | |
| 3/20/2018 | Robert W Duggan | Major Shareholder | Buy | 36,300 | $11.12 | $403,656.00 | 6,336,108 | |
| 3/15/2018 | Robert W Duggan | Major Shareholder | Buy | 49,660 | $11.36 | $564,137.60 | 6,294,808 | |
| 3/13/2018 | Kenneth J. Hillan | Insider | Sell | 2,735 | $11.74 | $32,108.90 | | |
| 3/12/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $11.39 | $227,800.00 | 6,255,148 | |
| 3/9/2018 | Robert W Duggan | Major Shareholder | Buy | 50,000 | $11.41 | $570,500.00 | 6,255,148 | |
| 3/2/2018 | Robert W Duggan | Major Shareholder | Buy | 527,396 | $10.31 | $5,437,452.76 | 5,697,752 | |
| 2/28/2018 | Robert W Duggan | Major Shareholder | Buy | 20,000 | $10.70 | $214,000.00 | 5,697,752 | |
| 2/21/2018 | Blake Wise | CEO | Sell | 1,640 | $10.67 | $17,498.80 | | |
| 2/21/2018 | Kenneth J. Hillan | Insider | Sell | 4,606 | $10.67 | $49,146.02 | | |
| 2/21/2018 | Tobin Schilke | CFO | Sell | 1,108 | $10.67 | $11,822.36 | | |
| 2/14/2018 | Robert W Duggan | Major Shareholder | Buy | 10,000 | $10.96 | $109,600.00 | 5,668,310 | |
| 1/5/2018 | Robert W Duggan | Major Shareholder | Buy | 50,000 | $11.51 | $575,500.00 | 5,617,752 | |
| 1/3/2018 | Robert W Duggan | Major Shareholder | Buy | 15,000 | $10.89 | $163,350.00 | 5,617,752 | |
| 12/18/2017 | Robert W Duggan | Major Shareholder | Buy | 95,012 | $11.13 | $1,057,483.56 | 5,602,752 | |
| 9/26/2017 | Blake Wise | COO | Sell | 3,576 | $15.99 | $57,180.24 | | |
| 9/26/2017 | Gary Loeb | General Counsel | Sell | 1,146 | $15.99 | $18,324.54 | | |
| 6/12/2017 | Tobin Schilke | CFO | Sell | 2,066 | $21.53 | $44,480.98 | | |
| 1/26/2017 | Gary Loeb | General Counsel | Sell | 521 | $16.78 | $8,742.38 | | |
| 1/26/2017 | Ian Friedland | Insider | Sell | 695 | $16.78 | $11,662.10 | | |
| 1/26/2017 | Kenneth J. Hillan | CEO | Sell | 1,431 | $16.78 | $24,012.18 | | |
| 1/26/2017 | Tobin Schilke | CFO | Sell | 955 | $16.78 | $16,024.90 | | |
| 1/26/2017 | Zeryn Sarpangal | VP | Sell | 781 | $16.78 | $13,105.18 | | |
| 12/19/2016 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 500,000 | $13.50 | $6,750,000.00 | | |
| 9/27/2016 | Blake Wise | COO | Sell | 3,632 | $4.30 | $15,617.60 | | |
| 9/27/2016 | Zeryn Sarpangal | VP | Sell | 1,069 | $4.30 | $4,596.70 | | |
| 3/17/2016 | Ian Friedland | Insider | Sell | 1,772 | $3.22 | $5,705.84 | 32,728 | |
| 3/17/2016 | Kenneth J Hillan | CEO | Sell | 3,572 | $3.22 | $11,501.84 | 61,628 | |
(Data available from 1/1/2013 forward)
Achaogen (NASDAQ AKAO) News Headlines
| Source: |
|
Achaogen (NASDAQ:AKAO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement
Achaogen (NASDAQ AKAO) Stock Chart for Monday, April, 23, 2018
Loading chart…
